Camelot Portfolios’s Labcorp LH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $514K | Buy |
1,835
+563
| +44% | +$148K | 0.36% | 110 |
|
|
2026
Q1 | $339K | Sell |
1,272
-54
| -4% | -$14.6K | 0.25% | 135 |
|
|
2025
Q4 | $333K | Sell |
1,326
-87
| -6% | -$23.1K | 0.2% | 134 |
|
|
2025
Q3 | $406K | Sell |
1,413
-874
| -38% | -$234K | 0.24% | 118 |
|
|
2025
Q2 | $600K | Sell |
2,287
-40
| -2% | -$9.74K | 0.36% | 92 |
|
|
2025
Q1 | $542K | Buy |
+2,327
| New | +$565K | 0.33% | 105 |
|
|
2024
Q3 | – | Sell |
-2,833
| Closed | -$577K | – | 367 |
|
|
2024
Q2 | $577K | Buy |
+2,833
| New | +$576K | 0.33% | 87 |
|
|
2024
Q1 | – | Sell |
-2,697
| Closed | -$613K | – | 174 |
|
|
2023
Q4 | $613K | Buy |
+2,697
| New | +$567K | 0.36% | 85 |
|
|
2023
Q3 | – | Sell |
-3,343
| Closed | -$693K | – | 168 |
|
|
2023
Q2 | $693K | Buy |
3,343
+495
| +17% | +$96K | 0.43% | 70 |
|
|
2023
Q1 | $561K | Buy |
2,848
+15
| +0.5% | +$3.09K | 0.39% | 79 |
|
|
2022
Q4 | $573K | Buy |
+2,833
| New | +$554K | 0.42% | 72 |
|
|
2022
Q3 | – | Sell |
-2,756
| Closed | -$555K | – | 188 |
|
|
2022
Q2 | $555K | Buy |
2,756
+26
| +1% | +$5.54K | 0.33% | 99 |
|
|
2022
Q1 | $618K | Sell |
2,730
-1,391
| -34% | -$327K | 0.31% | 101 |
|
|
2021
Q4 | $1.11M | Buy |
4,121
+1,034
| +33% | +$256K | 0.45% | 65 |
|
|
2021
Q3 | $746K | Sell |
3,087
-1,635
| -35% | -$412K | 0.38% | 78 |
|
|
2021
Q2 | $1.12M | Sell |
4,722
-338
| -7% | -$77K | 0.45% | 63 |
|
|
2021
Q1 | $1.11M | Buy |
5,060
+1,805
| +55% | +$362K | 0.46% | 67 |
|
|
2020
Q4 | $569K | Buy |
3,255
+596
| +22% | +$103K | 0.3% | 89 |
|
|
2020
Q3 | $430K | Buy |
2,659
+460
| +21% | +$72.9K | 0.27% | 94 |
|
|
2020
Q2 | $314K | Sell |
2,199
-1,118
| -34% | -$155K | 0.2% | 132 |
|
|
2020
Q1 | $360K | Buy |
3,317
+697
| +27% | +$100K | 0.2% | 131 |
|
|
2019
Q4 | $381K | Buy |
2,620
+252
| +11% | +$36.4K | 0.16% | 145 |
|
|
2019
Q3 | $342K | Buy |
2,368
+284
| +14% | +$41.4K | 0.16% | 145 |
|
|
2019
Q2 | $309K | Hold |
2,084
| – | – | 0.13% | 175 |
|
|
2019
Q1 | $274K | Hold |
2,084
| – | – | 0.11% | 195 |
|
|
2018
Q4 | $226K | Buy |
2,084
+355
| +21% | +$47.6K | 0.11% | 193 |
|
|
2018
Q3 | $258K | Buy |
1,729
+175
| +11% | +$26.6K | 0.12% | 175 |
|
|
2018
Q2 | $240K | Buy |
+1,554
| New | +$235K | 0.1% | 180 |
|
Other funds holding LH
Camelot Portfolios's LH Position: Q2 2026 in Review
Camelot Portfolios increased its Labcorp (LH) stake by 44% in Q2 2026, buying an estimated $148K and bringing the position to 1,835 shares worth $514K. The position accounts for 0.36% of the portfolio, ranked #110.
Camelot Portfolios first reported a position in LH in Q2 2018 and has held it in 28 quarters since. The position peaked at $1.12M in Q2 2021. 1,060 funds tracked by Wall St. Rank hold LH as of Q2 2026.
- Camelot Portfolios held 1,835 shares of Labcorp worth $514K as of Q2 2026.
- Camelot Portfolios bought 563 Labcorp shares in Q2 2026, an estimated $148K.
- Labcorp made up 0.36% of Camelot Portfolios's portfolio in Q2 2026, its #110 holding.
- Camelot Portfolios first reported a position in Labcorp in Q2 2018 and has held it in 28 quarters since.
- Camelot Portfolios's Labcorp position peaked at $1.12M in Q2 2021.
- 1,060 funds tracked by Wall St. Rank held Labcorp as of Q2 2026.
Based on Camelot Portfolios's 13F filing for Q2 2026, filed 17 Jul 2026.